-6.01 %
-22.61 %
-26.76 %
-56.14 %
-80.72 %
-85.33 %
-93.59 %
-99.77 %
-98.03 %
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read moreMarket cap
26.25M SEK
Turnover
180.13K SEK
Revenue
3.66M
EBIT %
-1,210.56 %
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 07.09.2026
